Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...

  • 1572156211176382465 Profile photo of Madelyn

    #TCT2022 SIMULTANEOUS PUBLICATION. In the EPIC-STEMI trial, routine early initiation of the PCSK9 inhibitor alirocumab reduced LDL-cholesterol by 22% in patients undergoing primary PCI compared with sham-control on a background of high-intensity statin. https://t.co/wB6vc1Toe3 - view on twitter

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions...